Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It works by relaxing vascular smooth muscle, thereby lowering blood pressure, and is prescribed for the treatment of hypertension in adult patients.

GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company adheres to stringent quality standards and provides reliable supply chain support for its customers.

Lercanidipine is a calcium channel blocker used to manage elevated blood pressure in various hypertension categories. - Essential hypertension: Lowers elevated systolic and diastolic pressure, helping achieve target blood pressure goals. - Secondary hypertension: Provides blood pressure control when hypertension is due to an identifiable cause. - Isolated systolic hypertension: Reduces high systolic readings, particularly in older adults.

Lercanidipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: Mild to moderate pain often occurring shortly after dosing. - Flushing: Warmth and redness of the skin, typically on the face or neck. - Peripheral edema: Swelling of the ankles or lower legs due to fluid accumulation. - Dizziness: Light‑headed sensation, especially when standing quickly. - Palpitations: Awareness of heartbeats, usually benign.

Serious or Rare Side Effects: - Angioedema: Rapid swelling of the face, lips, tongue, or throat requiring emergency care. - Severe hypotension: Markedly low blood pressure that can cause fainting or shock. - Myocardial infarction: Rare occurrence of heart attack, particularly in patients with existing coronary disease. - Hepatic dysfunction: Elevated liver enzymes or jaundice indicating liver injury.

Before initiating therapy with Lercanidipine, certain precautions should be considered. - Blood pressure monitoring: Regularly assess to avoid excessive hypotension. - Hepatic impairment: Use with caution; dose adjustment may be required. - Elderly patients: Start at the lowest effective dose due to increased sensitivity. - Concomitant antihypertensives: Adjust therapy to prevent additive blood pressure lowering. - Severe aortic stenosis: Contraindicated because of risk of precipitating heart failure. - Store at room temperature: Keep below 25 °C, retain in original packaging, and protect from moisture.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase plasma concentrations and risk of hypotension. - Concurrent use with other potent antihypertensives: Can cause additive blood pressure reduction. - Grapefruit juice: Inhibits CYP3A4 metabolism, raising drug levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): May reduce effectiveness. - Diuretics: May enhance electrolyte disturbances and orthostatic hypotension. - NSAIDs: Can attenuate antihypertensive response, requiring closer blood pressure monitoring.